{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:54:32Z","timestamp":1781733272270,"version":"3.54.5"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Per National Comprehensive Cancer Network guidelines for acute myeloid leukemia (AML), bone marrow (BM) evaluation is recommended after starting induction chemotherapy at 14 to 21\u2009days (mid-induction) and 30 to 35\u2009days (postinduction). Timely assessment of residual morphologic and molecular disease is challenging at these time points, given the low cellularity, the lack of CD34 or CD117 expression by blasts in most NPM1-mutated (NPM1mut) AML, and the longer turnaround time for molecular testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NPM1 mut AML undergoing BM evaluation at mid- and postinduction with concurrent flow cytometry and NPM1 real-time polymerase chain reaction or next-generation sequencing was evaluated. Different cell types positive by NPM1 immunohistochemistry (IHC) were enumerated, and the results were compared with flow cytometry and molecular findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NPM1 IHC demonstrated a sensitivity of 78% and 41% for detecting residual mutation at mid- and postinduction, respectively, with a positive predictive value ranging from 88% to 100%. Of 16 IHC-negative cases, 3 had no residual NPM1 mutation, 12 had very low-level mutation at a variant allele frequency of less than or equal to 21 transcripts, and only 1 had a high-level mutation in a markedly hypocellular BM. Of 24 IHC-positive cases, 22 had residual NPM1 mutation, and 2 showed false-positive staining in only a single cell with no residual NPM1 mutation. The level of IHC staining was mostly proportional to the level of residual mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mutation-specific NPM1 IHC is a valuable tool for a rapid assessment of residual morphologic and molecular disease in mid- and postinduction NPM1mut AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag062","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:27:58Z","timestamp":1777980478000},"source":"Crossref","is-referenced-by-count":0,"title":["Mutation-specific NPM1 immunohistochemistry is a sensitive method for detecting residual disease in mid- and postinduction bone marrows: comparison of NPM1 immunohistochemistry,\n                    <i>NPM1<\/i>\n                    real-time polymerase chain reaction, and flow cytometric studies"],"prefix":"10.1093","volume":"165","author":[{"given":"Ellie","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"Department of Pathology, Divisions of Hematopathology and Molecular Pathology, University of Colorado , Denver, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael G","family":"Bailey","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelynn E","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana P","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Rea","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-0132","authenticated-orcid":false,"given":"Nidhi","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-999X","authenticated-orcid":false,"given":"Sara A","family":"Monaghan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Jawad","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Hematopathology, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["United States"]},{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026061717315957900_aqag062-B1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026061717315957900_aqag062-B2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2026061717315957900_aqag062-B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/2643-3230.BCD-23-0144","article-title":"Criteria for diagnosis and molecular monitoring of NPM1-mutated AML","volume":"5","author":"Falini","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026061717315957900_aqag062-B4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/jha2.866","article-title":"Diagnostic utility of immunohistochemistry in detection of NPM1 mutations in acute myeloid leukemia with a patchy distribution","volume":"5","author":"Wei","year":"2024","journal-title":"EJHaem"},{"key":"2026061717315957900_aqag062-B5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026061717315957900_aqag062-B6","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"key":"2026061717315957900_aqag062-B7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood-2006-03-007013","article-title":"Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia","volume":"108","author":"Falini","year":"2006","journal-title":"Blood"},{"key":"2026061717315957900_aqag062-B8","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026061717315957900_aqag062-B9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/ijlh.13357","article-title":"Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation","volume":"43","author":"Arana Rosainz","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2026061717315957900_aqag062-B10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41408-023-00909-4","article-title":"Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study","volume":"13","author":"Matarraz","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026061717315957900_aqag062-B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cyto.b.21744","article-title":"Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1","volume":"96","author":"Zhou","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061717315957900_aqag062-B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40164-023-00449-4","article-title":"Identification of a novel NPM1 mutation in acute myeloid leukemia","volume":"12","author":"Yao","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2026061717315957900_aqag062-B13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag062\/68542855\/aqag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag062\/68542855\/aqag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:32:02Z","timestamp":1781731922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag062\/8709982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag062","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"aqag062"}}